Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
48 hedge funds and large institutions have $35.9M invested in Neos Therapeutics, Inc in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
4% more funds holding
Funds holding: 46 → 48 (+2)
35% less capital invested
Capital invested by funds: $55.1M → $35.9M (-$19.1M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.38M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$991K |
| 3 |
DA
DSC Advisors
Chicago,
Illinois
|
+$722K |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$548K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$545K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$7.86M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.35M |
| 3 |
DM
Deerfield Management
New York
|
-$1.82M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$396K |
| 5 |
PP
PDT Partners
New York
|
-$144K |
NEOS Hedge Fund Activity: Q3 2016 in Review
48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2016, worth a combined $35.9M — down 35% from $55.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NEOS positions and 3 closed out — a net gain of 2 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.38M. The largest seller was Sio Capital Management, exiting entirely with an estimated $7.86M sold.
- 48 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2016, up from 46 in Q2 2016.
- Funds reported $35.9M of Neos Therapeutics, Inc stock for Q3 2016, down 35% quarter-over-quarter.
- 5 funds opened new Neos Therapeutics, Inc positions in Q3 2016 and 3 closed out, a net change of +2 holders.
- The largest Neos Therapeutics, Inc buyer in Q3 2016 was Millennium Management, an estimated $2.38M added.
- The largest Neos Therapeutics, Inc seller in Q3 2016 was Sio Capital Management, an estimated $7.86M sold.
Based on aggregated 13F filings for Q3 2016.